BRCA1
L-Myc
UBR1
EGFR
TERT
EPCAM
XPC
ABL1
SMAD4
L-Myc
UBR1
EGFR
TERT
EPCAM
XPC
ABL1
SMAD4
November 6, 2026 at 12:53 PM
BRCA1
L-Myc
UBR1
EGFR
TERT
EPCAM
XPC
ABL1
SMAD4
L-Myc
UBR1
EGFR
TERT
EPCAM
XPC
ABL1
SMAD4
ICYMI at #ESMO2026 –
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China spkl.io/633217wXbW
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China spkl.io/633217wXbW
November 8, 2026 at 1:33 PM
ICYMI at #ESMO2026 –
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China spkl.io/633217wXbW
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China spkl.io/633217wXbW
Es sollte aber idealerweise die eGFR zuvor bestimmt sein
SAFETY FIRST
Metformin pausieren bei Erbrechen oder Durchfall mit unzureichender Flüssigkeitsaufnahme, bei Dyspnoe oder Sättigungsabfall sowie vor einer Kontrastmittelgabe.
SAFETY FIRST
Metformin pausieren bei Erbrechen oder Durchfall mit unzureichender Flüssigkeitsaufnahme, bei Dyspnoe oder Sättigungsabfall sowie vor einer Kontrastmittelgabe.
November 5, 2026 at 5:04 PM
Es sollte aber idealerweise die eGFR zuvor bestimmt sein
SAFETY FIRST
Metformin pausieren bei Erbrechen oder Durchfall mit unzureichender Flüssigkeitsaufnahme, bei Dyspnoe oder Sättigungsabfall sowie vor einer Kontrastmittelgabe.
SAFETY FIRST
Metformin pausieren bei Erbrechen oder Durchfall mit unzureichender Flüssigkeitsaufnahme, bei Dyspnoe oder Sättigungsabfall sowie vor einer Kontrastmittelgabe.
i’ll never blame u beautiful beans again
October 31, 2026 at 9:56 PM
i’ll never blame u beautiful beans again
Simple models rival a billion-parameter neural network in an EGFR binding assay. We gave Nextflow Frontier a task: rank molecules by how likely they are to bind EGFR, a cancer drug target. Frontier proposed models, ran them and used their scores to decide what to try next.🧵#NextflowFrontier
November 5, 2026 at 5:37 PM
Simple models rival a billion-parameter neural network in an EGFR binding assay. We gave Nextflow Frontier a task: rank molecules by how likely they are to bind EGFR, a cancer drug target. Frontier proposed models, ran them and used their scores to decide what to try next.🧵#NextflowFrontier
Dalton was 31 & training for a marathon when a lingering cough turned out to be stage 4 #lungcancer.
The marathon is still on his list.
“2027 is going to be my year.”
Share Dalton’s story. 💚
#HumansOfLungCancer @younglungcancer.bksy.social & EGFR Resisters
The marathon is still on his list.
“2027 is going to be my year.”
Share Dalton’s story. 💚
#HumansOfLungCancer @younglungcancer.bksy.social & EGFR Resisters
November 7, 2026 at 5:05 PM
Dalton was 31 & training for a marathon when a lingering cough turned out to be stage 4 #lungcancer.
The marathon is still on his list.
“2027 is going to be my year.”
Share Dalton’s story. 💚
#HumansOfLungCancer @younglungcancer.bksy.social & EGFR Resisters
The marathon is still on his list.
“2027 is going to be my year.”
Share Dalton’s story. 💚
#HumansOfLungCancer @younglungcancer.bksy.social & EGFR Resisters
Diagnosed with EGFR+ #lungcancer in 2022, Natasha was told it was incurable & inoperable.
Last Oct , she had surgery to remove part of her lung, despite the cancer having spread to her brain.
Now she’s training to teach yoga to people with cancer & lives with hope 💟
allyouneedislungs.org.uk #LCAM
Last Oct , she had surgery to remove part of her lung, despite the cancer having spread to her brain.
Now she’s training to teach yoga to people with cancer & lives with hope 💟
allyouneedislungs.org.uk #LCAM
November 5, 2026 at 1:27 PM
Diagnosed with EGFR+ #lungcancer in 2022, Natasha was told it was incurable & inoperable.
Last Oct , she had surgery to remove part of her lung, despite the cancer having spread to her brain.
Now she’s training to teach yoga to people with cancer & lives with hope 💟
allyouneedislungs.org.uk #LCAM
Last Oct , she had surgery to remove part of her lung, despite the cancer having spread to her brain.
Now she’s training to teach yoga to people with cancer & lives with hope 💟
allyouneedislungs.org.uk #LCAM
(US20260337278A1) disclosing tetravalent Fab-scFv antibodies targeting two EGFR epitopes. Systimmune reports enhanced ADCC potency in EGFRvIII models versus wild-type EGFR, with selected constructs outperforming parental SI-95m4 (EC50 19.3 nM). Selectivity in normal tissues remains to be validated.
November 8, 2026 at 11:47 AM
(US20260337278A1) disclosing tetravalent Fab-scFv antibodies targeting two EGFR epitopes. Systimmune reports enhanced ADCC potency in EGFRvIII models versus wild-type EGFR, with selected constructs outperforming parental SI-95m4 (EC50 19.3 nM). Selectivity in normal tissues remains to be validated.
Leah is more than her diagnosis. 🤍
There’s a whole life beyond the appointments and scans—and Leah is giving us a glimpse.
Camel adventures included. 🐪
See the person behind the diagnosis.
#HumansOfLungCancer with @younglungcancer.bsky.social & EGFR Resisters #LCAM26
There’s a whole life beyond the appointments and scans—and Leah is giving us a glimpse.
Camel adventures included. 🐪
See the person behind the diagnosis.
#HumansOfLungCancer with @younglungcancer.bsky.social & EGFR Resisters #LCAM26
November 7, 2026 at 11:30 AM
Leah is more than her diagnosis. 🤍
There’s a whole life beyond the appointments and scans—and Leah is giving us a glimpse.
Camel adventures included. 🐪
See the person behind the diagnosis.
#HumansOfLungCancer with @younglungcancer.bsky.social & EGFR Resisters #LCAM26
There’s a whole life beyond the appointments and scans—and Leah is giving us a glimpse.
Camel adventures included. 🐪
See the person behind the diagnosis.
#HumansOfLungCancer with @younglungcancer.bsky.social & EGFR Resisters #LCAM26
Estou no Congresso da SBOC, Sociedade Brasileira de Oncologia Clínica, no RJ. Sou paciente, câncer de pulmão, avançado, EGFR exon 19 mutado, em tratamento de 1 linha. Farei relato de paciente sobre oncogenômica numa palestra. Vou falar das discussões que estou acompanhando.
November 5, 2026 at 2:03 PM
Estou no Congresso da SBOC, Sociedade Brasileira de Oncologia Clínica, no RJ. Sou paciente, câncer de pulmão, avançado, EGFR exon 19 mutado, em tratamento de 1 linha. Farei relato de paciente sobre oncogenômica numa palestra. Vou falar das discussões que estou acompanhando.
American University of Sharjah has won a third US patent for an ultrasound-triggered liposome delivery system targeting EGFR-positive breast tumours with chemotherapy.
AUS wins third US patent for antibody-guided breast cancer drug delivery
American University of Sharjah has patented a cetuximab-targeted liposome method using ultrasound to release chemotherapy at EGFR-positive breast tumours.
thebiotechtimes.com
November 7, 2026 at 5:00 AM
American University of Sharjah has won a third US patent for an ultrasound-triggered liposome delivery system targeting EGFR-positive breast tumours with chemotherapy.
Simple models rival a billion-parameter neural network in an EGFR binding assay. We gave Nextflow Frontier a task: rank molecules by how likely they are to bind EGFR, a cancer drug target. Frontier proposed models, ran them and used their scores to decide what to try next.🧵#NextflowFrontier
November 5, 2026 at 5:39 PM
Simple models rival a billion-parameter neural network in an EGFR binding assay. We gave Nextflow Frontier a task: rank molecules by how likely they are to bind EGFR, a cancer drug target. Frontier proposed models, ran them and used their scores to decide what to try next.🧵#NextflowFrontier
Herboxidiene and EGFR expression in A172 glioblastoma cells https://www.biorxiv.org/content/10.64898/2026.11.02.762382v1
November 4, 2026 at 7:17 AM
Herboxidiene and EGFR expression in A172 glioblastoma cells https://www.biorxiv.org/content/10.64898/2026.11.02.762382v1
📢🚨🔬💻Publication: How cells decide what proteins to destroy 🧵
Cells must constantly decide which proteins to keep or to destroy. Growth factor receptors like EGFR are a key example—after signaling, they must be degraded. But how does the cell ensure this?
www.sciencedirect.com/science/arti... 1/8
Cells must constantly decide which proteins to keep or to destroy. Growth factor receptors like EGFR are a key example—after signaling, they must be degraded. But how does the cell ensure this?
www.sciencedirect.com/science/arti... 1/8
www.sciencedirect.com
November 6, 2026 at 10:51 AM
📢🚨🔬💻Publication: How cells decide what proteins to destroy 🧵
Cells must constantly decide which proteins to keep or to destroy. Growth factor receptors like EGFR are a key example—after signaling, they must be degraded. But how does the cell ensure this?
www.sciencedirect.com/science/arti... 1/8
Cells must constantly decide which proteins to keep or to destroy. Growth factor receptors like EGFR are a key example—after signaling, they must be degraded. But how does the cell ensure this?
www.sciencedirect.com/science/arti... 1/8
Herboxidiene and EGFR expression in A172 glioblastoma cells https://www.biorxiv.org/content/10.64898/2026.11.02.762382v1
November 4, 2026 at 7:17 AM
Herboxidiene and EGFR expression in A172 glioblastoma cells https://www.biorxiv.org/content/10.64898/2026.11.02.762382v1
I can’t stop listening to this
www.youtube.com/watch?v=EGfR...
www.youtube.com/watch?v=EGfR...
Winona Fighter - LEECH (Official Video)
YouTube video by riserecords
www.youtube.com
November 5, 2026 at 4:30 AM
I can’t stop listening to this
www.youtube.com/watch?v=EGfR...
www.youtube.com/watch?v=EGfR...
Thanks.
This is a major breakthrough in a pivotal trial.
Petosemtamab is an immunoglobulin G1 bispecific antibody targeting EGFR and LGR5.
The FDA is likely to approve the combination in 2027.
This is a major breakthrough in a pivotal trial.
Petosemtamab is an immunoglobulin G1 bispecific antibody targeting EGFR and LGR5.
The FDA is likely to approve the combination in 2027.
November 3, 2026 at 10:08 PM
Thanks.
This is a major breakthrough in a pivotal trial.
Petosemtamab is an immunoglobulin G1 bispecific antibody targeting EGFR and LGR5.
The FDA is likely to approve the combination in 2027.
This is a major breakthrough in a pivotal trial.
Petosemtamab is an immunoglobulin G1 bispecific antibody targeting EGFR and LGR5.
The FDA is likely to approve the combination in 2027.
Cells lacking HRS phosphorylation sites worked perfectly fine! EGFR was still sorted and degraded normally. This challenged decades of assumptions about how this system works 4/8
November 6, 2026 at 10:51 AM
Cells lacking HRS phosphorylation sites worked perfectly fine! EGFR was still sorted and degraded normally. This challenged decades of assumptions about how this system works 4/8
‼️ TODAY ‼️ is the last day to get your Iterative Mapping Grant Program applications in! Don't miss your chance to be one of the first to use the Nautilus Voyager™ Platform to generate novel insights into the roles EGFR or AKT1 proteoforms play in cancer biology.
www.nautilus.bio/iterative-ma...
www.nautilus.bio/iterative-ma...
Iterative Mapping Grant Program ~ Nautilus Biotechnology
www.nautilus.bio
November 6, 2026 at 7:04 PM
‼️ TODAY ‼️ is the last day to get your Iterative Mapping Grant Program applications in! Don't miss your chance to be one of the first to use the Nautilus Voyager™ Platform to generate novel insights into the roles EGFR or AKT1 proteoforms play in cancer biology.
www.nautilus.bio/iterative-ma...
www.nautilus.bio/iterative-ma...
13/ Results: Correlations
🧠Low Mg was not correlated with eGFR, PTH, or calcium levels
🧠Low Mg was found in whole gene deletion, frameshift, missense, and splice site variants, but no known hot spots
🧠Patients with full triad were more likely to have low Mg
🧠Low Mg was not correlated with eGFR, PTH, or calcium levels
🧠Low Mg was found in whole gene deletion, frameshift, missense, and splice site variants, but no known hot spots
🧠Patients with full triad were more likely to have low Mg
November 4, 2026 at 9:25 PM
13/ Results: Correlations
🧠Low Mg was not correlated with eGFR, PTH, or calcium levels
🧠Low Mg was found in whole gene deletion, frameshift, missense, and splice site variants, but no known hot spots
🧠Patients with full triad were more likely to have low Mg
🧠Low Mg was not correlated with eGFR, PTH, or calcium levels
🧠Low Mg was found in whole gene deletion, frameshift, missense, and splice site variants, but no known hot spots
🧠Patients with full triad were more likely to have low Mg
How it works: it's a dual-targeted antibody that blocks two growth signals cancer uses — EGFR and MET. It's given as an injection under the skin every 3 weeks, not an IV infusion.
November 6, 2026 at 4:23 PM
How it works: it's a dual-targeted antibody that blocks two growth signals cancer uses — EGFR and MET. It's given as an injection under the skin every 3 weeks, not an IV infusion.
UPDATE: Johnson & Johnson's RYBREVANT FASPRO wins FDA accelerated approval as the first dual EGFR/MET therapy for recurrent or metastatic head and neck squamous cell carcinoma, expanding beyond lung cancer.
November 6, 2026 at 2:08 AM
UPDATE: Johnson & Johnson's RYBREVANT FASPRO wins FDA accelerated approval as the first dual EGFR/MET therapy for recurrent or metastatic head and neck squamous cell carcinoma, expanding beyond lung cancer.
A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed. www.tandfonline.com/doi/abs/10.1... #hvhebron #onco [Text complet]
A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed
Published in Future Oncology (Vol. 22, No. 23, 2026)
www.tandfonline.com
November 6, 2026 at 10:16 AM
A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed. www.tandfonline.com/doi/abs/10.1... #hvhebron #onco [Text complet]